Clinical trial
Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
NCT00002723
Study timeline
Study start (unknown)1996-01-01Date precision: month
Registry last updated2013-02-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
Sponsors & collaborators
National Cancer Institute (NCI)lead sponsor
SWOG Cancer Research Networkcollaborator
Eastern Cooperative Oncology Groupcollaborator
Mapped research locations
ChicagoIllinois, United States2NashvilleTennessee, United States2MilwaukeeWisconsin, United States2MadisonWisconsin, United States2BostonMassachusetts, United States1ClevelandOhio, United States1MinneapolisMinnesota, United States1Ann ArborMichigan, United States1The BronxNew York, United States1ToledoOhio, United States1FargoNorth Dakota, United States1Sioux FallsSouth Dakota, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00002723 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.